Mast cell stabilization with ketotifen decreases il-13 and cgrp in the ascitic fluid of rats with microsurgical cholestasis

• Aller-Reyero, MA ^[1] ; Tavares, E ^[2] ; Arias, A ^[3] ; Cuervas-Mons, V ^[3] ; Miñano, FJ ^[2] ; Arias, J ^[1]
  1. [1] Universidad Complutense de Madrid

     Universidad Complutense de Madrid

     Madrid, España

     
  2. [2] Clinical and Experimental Pharmacology Unit. Valme Virgen University Hospital. University of Sevilla, Sevilla, Spain.
  3. [3] Internal Medicine Department. Puerta de Hierro Hospital. Autonoma University of Madrid. Spain.

  Mostrar afiliaciones +
• Localización: Revista española de investigaciones quirúrgicas, ISSN 1139-8264, Vol. 21, Nº. 1, 2018, págs. 3-7
• Idioma: inglés
• Enlaces
  • Texto Completo Ejemplar
• Resumen

  • Ascites is one of the most severe complications of cirrhosis with portal hypertension. Since mast cells by type 2 immunity could be involved in the production of portal hypertensive ascites, we are studying the effectiveness of Ketotifen administration, a mast cell stabilizer, to modulate the production of interleukin-13, a type-2 associated cytokine, as well as calcitonin gene-related peptide (CGRP), one important regulator of its production, in the ascitic fluid of microsurgical extrahepatic cholestatic rats. The increased IL-13 and CGRP release in the ascitic fluid of the rats with obstructive cholestasis and its significant reduction after both, prophylactic plus therapeutic and delayed therapeutic oral administration of Ketotifen, allows for proposing that mast cells could play an important role in the etiopathogeny of portal hypertensive ascites.